Navigation Links
Lytix Presents LTX-109 Anti-Microbial Data at ICAAC
Date:11/20/2008

TROMSO, Norway, November 20 /PRNewswire/ -- The Scandinavian-based drug development company Lytix Biopharma has announced results of studies on its lead antimicrobial candidate LTX-109. Presented at ICAAC in Washington, DC, the studies showed that the novel lytic peptidomimetic has an ultra-rapid bacteriocidal effect, significantly better towards killing Staphylococcus aureus and Streptococcus pyogenes than marketed gold standard drugs. In addition to this it has proven effective against a wide range of 110 European Pseudomonas aeruginosa clinical isolates, a problrmatic Gram (-) bacterium.

According to Lytix Biopharma spokesperson Anders Fugelli, these are important studies: "The fact that LTX-109 is effective against a broad range of pathogens highlights its potential utility as a truly novel broad spectrum antimicrobial drug. Indeed it is so effective, that although the initial formulation is for the treatment of skin infections, we could now consider it for other indications such as skin and nail fungal infections, acne and oropharyngeal candidaisis. We are now in the final stages of preclinical development and look forward to taking LtX-109 into the clinic in during the second half of 2009."

LTX-109 is a novel synthetic antimicrobial pepitidomimetic (SAMP) drug with a rapid bactericidal mode of action that can effectively synthesized in scalable, low-cost chemical reactor systems.

About Lytix Biopharma AS

Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as first-in-class oncology treatments. Lytix was established in 2003 to commercialise world-class research in the field of lytic peptides spun out by the founding scientists working in the University Hospital and University of Tromso in Norway.

Operating out of a main office located in Tromso and through our continued collaboration with the University o
'/>"/>

SOURCE Lytix Biopharma AS
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
2. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
3. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
4. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
5. Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
6. Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections
7. Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
8. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
9. Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
10. Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
11. Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  TeamHealth Medical Call Center (THMCC), a premier ... lines, announces its newly formed Clinical Advisory Committee. ... leaders, provides clinical expertise to advance THMCC,s purpose ... hospital clients, physician clients and patients. ... imperative to continuously advance our services and improve ...
(Date:5/23/2013)... Calif. , May 23, 2013 Anthem ... program that would have required them to obtain their ... by Consumer Watchdog and Whatley Kallas LLC.  ... Superior Court, alleged that Blue Cross,s mandatory mail order ... threatening their health and privacy. "This settlement ...
(Date:5/23/2013)... , May 23, 2013  Spring Bank Pharmaceuticals, ... treatment of viral infections, today announced that it has ... 9200, its investigational, once daily, oral therapy for the ... healthy, HCV-infected patients and is designed to assess both ... 9200 is a first-in-class drug for the treatment of ...
Breaking Medicine Technology:TeamHealth Medical Call Center Forms Clinical Advisory Committee 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3
... 23, 2007 - CytoGenix, Inc. (CYGX.OB),announced today that ... update on preclinical animal data for DNA vaccines ... 2007,DNA Vaccines conference to be held in Malaga, ... comments, "We have successfully conducted tests of,synDNA(TM) based ...
... VANCOUVER, British Columbia--(BUSINESS WIRE)--May 23, 2007 -,ProtoKinetix Inc. ... by ITTEC Stem, Inc. at the University of ... for stem cells demonstrate the vital importance of ... This is the,first series of tests using AAGP(TM) ...
Cached Medicine Technology:CytoGenix to Present at 2007 International DNA Vaccines Conference,in Spain 2ProtoKinetix's AAGP Dramatically Increases Recovery Rate of,Cryopreserved Stem Cells 2
(Date:5/23/2013)... dragged to its destruction inside a cell, a ... that thwart the development of tumor-suppressing microRNAs (miRNAs) ... online publication at Nature . , Under ... the epidermal growth factor receptor (EGFR) gums up ... by scientists at The University of Texas MD ...
(Date:5/23/2013)... York (PRWEB) May 23, 2013 ... C.R. Bard, Inc., continue to move forward in a ... District of West Virginia, Bernstein Liebhard LLP reports. ... denied a request by C.R. Bard to seal emails ... trade secrets and other confidential, proprietary information about its ...
(Date:5/23/2013)... New York, NY (PRWEB) May 23, 2013 ... http://bit.ly/Z4m6UI , Canadian tech start-ups are increasingly seeing ... deals with larger US-based companies, according to ... business development engine. , The company has compiled ... entitled Borderless Investments. The findings of the research have ...
(Date:5/23/2013)... May 23, 2013 EnvirOasis, the leader ... and ESCO market is pleased to announce its new ... Listed LED products. EnvirOasis has been a market ... and retrofit kits and has recently brought to market ... (Light Emitting Diode) is energy efficient lighting technology which ...
(Date:5/23/2013)... HealthDay Reporter , , THURSDAY, May 23 (HealthDay News) ... as badly as methamphetamine or crack cocaine, a new ... ,meth mouth, or ,coke mouth, it is startling to ... less the same," said Dr. Mohamed Bassiouny, a professor ... Dentistry in Philadelphia. Methamphetamine, crack cocaine and soda ...
Breaking Medicine News(10 mins):Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 3Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 2Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 3Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 4Health News:EnvirOasis Lighting Announces Energy Star and Design Lights Consortium LED Products 2Health News:Diet Soda Habit as Bad for Teeth as Meth Addiction, Study Claims 2Health News:Diet Soda Habit as Bad for Teeth as Meth Addiction, Study Claims 3
... SOUTH SAN FRANCISCO, Calif., July 7 Catalyst Biosciences, ... research and license agreement with MedImmune, the global biologics ... that specifically degrade or modulate two targets, one of ... , Catalyst will receive undisclosed upfront licensing fees, full-time ...
... is a fully equipped bio-safety level 2 laboratory dedicated exclusively ... Affairs for Medizone. "This new laboratory is located in ... the country and will provide a primary research and development ... now a clear path to commercialization with its lead product, ...
... 2009 AMERIGROUP Corporation (NYSE: AGP ) today ... quarter ended June 30, 2009, at approximately 6:00 a.m. Eastern ... Eastern Time on the same day, AMERIGROUP,s management will host ... information. , , To listen to the call, dial ...
... GROVE, Ill., July 7 Lifeway Foods, Inc. (Nasdaq: ... of other natural and organic dairy products, invites you to come ... the first pitch before the Chicago Cubs take on the Atlanta ... this official "Lifeway Day with the Cubs," the local kefir manufacturer ...
... July 7 CSC (NYSE: CSC ) today ... in multiple categories of Celent,s 2009 Insurance Software Deal Trends ... research and advisory firm, reported in the Life/Health Edition that ... Processing with 56 percent of the deals in 2007 and ...
... 7 Rho Luxfeyr does not want to be labeled as ... that she offers via her Web site ( http://rho-luxfeyr.com ) extend ... tellers focus on predicting the future, which is really no help ... can be constructed or changed by will or intent," said Luxfeyr. ...
Cached Medicine News:Health News:Catalyst Biosciences Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics 2Health News:Medizone International, Inc. (MZEI.PK) Announces it has Established its Own BSL2A Certified Laboratory Located in Innovation Park, Queen's University at Kingston, Ontario, Canada. 2Health News:AMERIGROUP Corporation to Discuss Second Quarter Earnings on July 31 2Health News:Giant Bugs Invade Wrigley Field 2Health News:CSC Cited as a Leading Technology Provider in Celent Insurance Software Study 2Health News:Unique Intuitive Service Helps Clients Improve Their Lives 2
... monochromatic and chromatic correction for the focal ... completely flat images for observation and photomicrography ... of wavelengths up to the near UV ... glass types of low autofluorescence makes these ...
... The CFI Fluor 20x Water ... physiology and brain research where the ... exposed living tissue or brain slice. ... bright fluorescent signals with a numberical ...
Inquire...
... 63x/1.25 Oil Ph3 Antiflex is ... contrast. This method reveals structures ... such as cells adhering to ... dish. Moreover, this objective is ...
Medicine Products: